However, the publication by Takahashi et al is not without its flaws. It is inevitable to question whether careful patient selection might have played a role as previously described in a previous communication by Slotman.46 On an average, participating centers enrolled only one patient per year and the high proportion of patients who received second-, third- and fourth-line chemotherapy is incongruent with previously published data49 and might reflect this assumption. In addition, in stark contrast to the EORTC trial, a higher proportion of patients received radiotherapy in the observation arm of the Japanese trial (25% vs. 58%). Le Péchoux et al described extensively similar 1-year survival rates in the subgroup analysis of ES-SCLC patients of the landmark PCI meta-analysis published in 1999.4,49Differences in survival outcome between both studies were also attributed to several factors including eligibility criteria, patient selection, treatment regimens (chemotherapy and PCI fractionation), demographics as well as possibly related to host-related genetic differences in SCLC between Asian and non-Asian populations.49
However, a retrospective study emanating from Germany demonstrated a stark improved median overall survival after PCI in ES-SCLC patients in comparison to the EORTC trial (12 vs. 6.7 months) and similar to the results of the Japanese trial.50 However, as the authors duly noted, according to institutional policy, the study population comprised a select group of patients with relatively good performance status (median ECOG 1) with exclusion of older patients and patients at high risk for cognitive decline.
PCI vs. active MRI surveillance with access to stereotactic radiotherapy (SRT)
Based on the conflicting results of the EORTC and Japanese trials, the NCCN softened its latest recommendation for PCI in ES-SCLC to “consider”. However, in patients not receiving PCI, a comprehensive MRI surveillance program in accordance with the above-mentioned study is paramount.
Furthermore, there is uncertainty regarding use of SRT for brain relapse (single or multiple) in SCLC. There are some retrospective data supporting its use.
A secondary analysis of the Japanese trial noted that 25/54 (46%) patients in the PCI arm received repeat radiotherapy with stereotactic radiosurgery (SRS) the preferred modality as is popularly adopted in the authors’ country of origin.51
In a recent NCDB analysis of 5952 SCLC patients by Robin et al, upfront SRS was associated with improved median OS vs. upfront WBRT +/− SRS (10.8 vs. 7.1 months, HR 0.65, 95% CI 0.55–0.75, p<0.001), which persisted on multivariate analysis controlling for comorbidities, extracranial metastases, age, race/ethnicity and sex (HR 0.70, 95% CI 0.60–0.81, p <0.001). However, the results must be interpreted with caution as the SRS arm was underpowered with 200 vs. 5752 patients in the WBRT arm.52
Also in patients with single brain metastasis, Bernhardt et al recently described prognostic factors and demonstrated in a retrospective analysis of 52 patients that, prior surgery, synchronous as opposed to metachronous metastasis and response to primary chemotherapy was associated with improved OS.53
Currently, a Phase 2 study in Germany comparing WBRT alone to SRS for SCLC patients is recruiting to this effect (NCT03297788) and might provide a basis for further investigation of this strategy within the ramifications of a Phase 3 study.
It is imminently paramount that the TNM classification according to the UICC 8th edition is universally adopted for SCLC.54 Subsequently, survival benefit conferred by PCI in LS-SCLC could be further elucidated.
Since its initial proposal for SCLC in 1973 and recommendation in 1999, PCI has been the topic of recurring interest and debate. It is inevitable that we are slowly arriving at a defining crossroad as new data emanating from studies in the current MRI era and ubiquity of comprehensive brain imaging suggest that the modest survival benefit alluded to PCI may be less than previously anticipated, especially in ES-SCLC. Thus, further studies are urgently required to dispel these uncertainties.
However, the best strategy moving forward is probably integrating hippocampal avoidance and drug neuroprotection to minimize neuropsychological sequelae. Additionally, regarding the question of PCI in the elderly, there are some question marks that remain but, in our opinion, shared decision making is the pinnacle of patient-centered care. Subsequently, the next step, strictly hypothesis-generating would be evaluating possible dose de-escalation in elderly patients.
The authors report no conflicts of interest in this work.
Farkhad Manapov,1,2 Lukas Käsmann,1 Olarn Roengvoraphoj,1 Maurice Dantes,1 Nina-Sophie Schmidt-Hegemann,1 Claus Belka,1,2 Chukwuka Eze1
1Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; 2Comprehensive Pneumology Center Munich (CPC-M), Munich, Germany
1. Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21(10):2244–2255.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
3. Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E; ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl_6):vi99–vi105.
4. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341(7):476–484.
5. Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. J Natl Compr Cancer Netw. 2013;11(1):78–98.
6. Slotman B, Faivre-Finn C, Kramer G, et al; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–672.
7. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms—results of an International Phase III Randomized Controlled Trial by the EORTC radiation oncology and lung cancer groups. J Clin Oncol. 2009;27(1):78–84.
8. Käsmann L, Bolm L, Schild SE, Janssen S, Rades D. Neutrophil-to-lymphocyte ratio predicts outcome in limited disease small-cell lung cancer. Lung. 2017;195(2):217–224.
9. Manapov F, Klautke G, Fietkau R. Prevalence of brain metastases immediately before prophylactic cranial irradiation in limited disease small cell lung cancer patients with complete remission to chemoradiotherapy: a single institution experience. J Thorac Oncol. 2008;3(6):652–655.
10. Le Péchoux C, Dunant A, Senan S, et al; Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10(5):467–474.
11. Schild SE, Foster NR, Meyers JP, et al; North Central Cancer Treatment Group. Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol. 2012;23(11):2919–2924.
12. Manapov F, Niyazi M, Gerum S, et al. Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy. BMC Cancer. 2016;16(1):216.
13. Rades D, Kaesmann L, Janssen S, Schild SE. A new score for estimating survival after definitive radiochemotherapy of limited disease small cell lung cancers. Lung. 2016;194(4):625–629.
14. Käsmann L, Janssen S, Rades D. Prognostic factors including the expression of Thyroid Transcription Factor 1 (TTF1) in patients irradiated for limited-disease small cell lung cancer. Anticancer Res. 2016;36(7):3499–3503.
15. Roengvoraphoj O, Eze C, Niyazi M, et al. Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy. Strahlenther Onkol. 2017;193(2):150–155.
16. Eze C, Roengvoraphoj O, Niyazi M, et al. Treatment response and prophylactic cranial irradiation are prognostic factors in a real-life limited-disease small-cell lung cancer patient cohort comprehensively staged with cranial magnetic resonance imaging. Clin Lung Cancer. 2017;18(4):e243–e249.
17. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36–42.
18. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–671.
19. Lee JS, Umsawasdi T, Lee YY, et al. Neurotoxicity in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys. 1986;12(3):313–321.
20. Redmond KJ, Hales RK, Anderson-Keightly H, et al. Prospective study of hippocampal-sparing prophylactic cranial irradiation in limited-stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;98(3):603–611.
21. Gondi V, Tome WA, Marsh J, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol. 2010;95(3):327–331.
22. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810–3816.
23. Lok BH, Ma J, Foster A, et al. Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Adv Radiat Oncol. 2017;2(4):548–554.
24. Bennett BM, Wells JR, Panter C, Yuan Y, Penrod JR. The humanistic burden of small cell lung cancer (SCLC): a systematic review of health-related quality of life (HRQoL) literature. Front Pharmacol. 2017;8:339.
25. Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a Phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):77–84.
26. Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non–small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29(3):279–286.
27. Simó M, Vaquero L, Ripollés P, et al. Longitudinal brain changes associated with prophylactic cranial irradiation in lung cancer. J Thorac Oncol. 2016;11(4):475–486.
28. Kalm M, Abel E, Wasling P, et al. Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys. 2014;89(3):607–614.
29. Korkmaz Kirakli E, Oztekin O. Is hippocampal avoidance during whole-brain radiotherapy risky for patients with small-cell lung cancer? hippocampal metastasis rate and associated risk factors. Technol Cancer Res Treat. 2017;16(6):1202–1208.
30. Liu M. Professor David Ball: prophylactic cranial irradiation (PCI) benefits patients with SCLC. Transl Lung Cancer Res. 2018;7(Suppl 1):S81–S82.
31. Brown PD, Pugh S, Laack NN, et al; Radiation Therapy Oncology Group (RTOG). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429–1437.
32. Rapp SR, Case LD, Peiffer A, et al. Donepezil for irradiated brain tumor survivors: a Phase III randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33(15):1653–1659.
33. Abdel-Rahman O. Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis. Clin Respir J. 2018;12(3):1093–1099.
34. Ludbrook JJ, Truong PT, MacNeil MV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys. 2003;55(5):1321–1330.
35. Rossi A, Maione P, Colantuoni G, et al. Treatment of small cell lung cancer in the elderly. Oncologist. 2005;10(6):399–411.
36. Farooqi AS, Holliday EB, Allen PK, Wei X, Cox JD, Komaki R. Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: Do all patients benefit? Radiother Oncol. 2017;122(2):307–312.
37. Johnson BE, Patronas N, Hayes W, et al. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 13-year survivors. J Clin Oncol. 1990;8(1):48–56.
38. Shaw E, Su J, Eagan R, Jett J, Maksymiuk A, Deigert F. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol. 1994;12(11):2327–2332.
39. Glantz MJ, Choy H, Yee L. Prophylactic cranial irradiation in small cell lung cancer: rationale, results, and recommendations. Semin Oncol. 1997;24(4):477–483.
40. Eaton BR, Kim S, Marcus DM, et al. Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer. Cancer. 2013;119(21):3753–3760.
41. Damhuis RA, Senan S, Belderbos JS. Usage of prophylactic cranial irradiation in elderly patients with small-cell lung cancer. Clin Lung Cancer. 2018;19(2):e263–e267.
42. Eze C, Roengvoraphoj O, Manapov F. Prophylactic cranial irradiation in resected early stage small cell lung cancer. Int J Radiat Oncol. 2017;98(3):612–614.
43. Eze C, Roengvoraphoj O, Manapov F. Prophylactic cranial irradiation in resected small cell lung cancer: comprehensive staging, adjuvant chemotherapy, and strict stratification of pathological stage play a role. J Thorac Oncol. 2017;12(9):e137–e138.
44. Stahl JM, Corso CD, Verma V, et al. Trends in stereotactic body radiation therapy for stage I small cell lung cancer. Lung Cancer. 2017;103:11–16.
45. Yang CF, Chan DY, Speicher PJ, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol. 2016;34(10):1057–1064.
46. Slotman BJ. Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer? Lancet Oncol. 2017;18(5):566–567.
47. Manapov F, Eze C. Prophylactic cranial irradiation in small-cell lung cancer. Lancet Oncol. 2017;18(7):e366.
48. Nosaki K, Seto T, Shimokawa M, Takahashi T, Yamamoto N. Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy? Radiother Oncol. 2018;127(3):344–348.
49. Le Pechoux C, Botticella A, Levy A, Auperin A. Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again? J Thorac Dis. 2017;9(11):4157–4161.
50. Bernhardt D, Adeberg S, Bozorgmehr F, et al. Nine-year experience: prophylactic cranial irradiation in extensive disease small-cell lung cancer. Clin Lung Cancer. 2017;18(4):e267–e271.
51. Akamatsu H, Takahashi T, Yamamoto N. Prophylactic cranial irradiation in small-cell lung cancer – Authors’ reply. Lancet Oncol. 2017;18(7):e369.
52. Robin TP, Jones BL, Amini A, et al. Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer. Lung Cancer. 2018;120:88–90.
53. Bernhardt D, Adeberg S, Bozorgmehr F, et al. Outcome and prognostic factors in single brain metastases from small-cell lung cancer. Strahlenther Onkol. 2018;194(2):98–106.
54. Goldstraw P, Chansky K, Crowley J, et al; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.
Source: Lung Cancer: Targets and Therapy.
Originally published August 16, 2018.